Biological immortality

AgeX Therapeutics to Present at Investing in the Age of Longevity Conference

Retrieved on: 
Friday, November 8, 2019
Research, Pharmaceutical, Consumer, Medical devices, Hospitals, Genetics, Clinical trials, Science, Biotechnology, Stem cells, Seniors, Health, Branches of biology, Biology, Senescence, Articles, Stem cells, Immortality, Emerging technologies, Healing, Regeneration, Biological immortality, Ageing, Cell therapy, Branches of biology, Biology, Senescence, Articles, Stem cells, Immortality, Emerging technologies, Healing, Regeneration, Biological immortality, Ageing, Cell therapy

AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at Investing in the Age of Longevity , organized by Master Investor, Ltd. , on Wednesday, November 13 at Science Gallery London .

Key Points: 
  • AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at Investing in the Age of Longevity , organized by Master Investor, Ltd. , on Wednesday, November 13 at Science Gallery London .
  • AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.
  • AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues.
  • Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

AgeX Therapeutics Publishes Theoretical Basis of Human Cell Age-Reversal in the Journal Regenerative Medicine

Retrieved on: 
Wednesday, September 4, 2019
Science, Stem cells, Biotechnology, Research, Oncology, Health, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Induced stem cells, Immortality, Biological immortality, Cell therapy, Reprogramming

We believe that it is now possible to collate the diverse observations about aging into a unified model.

Key Points: 
  • We believe that it is now possible to collate the diverse observations about aging into a unified model.
  • The paper explores the mechanisms of aging and shares important insights into molecular biology of cell aging and immortalization, as well as the mechanisms of cell age reversal by somatic cell nuclear transfer and transcriptional reprogramming.
  • AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.
  • AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.